Memantine, an NMDA receptor antagonist, has shown potential in managing Visual Snow Syndrome by modulating glutamatergic neurotransmission and reducing aberrant cortical hyperexcitability. By blocking excessive glutamate signaling, it may help mitigate the persistent visual disturbances and neurological symptoms associated with the syndrome, potentially restoring more normalized neural processing in visual and sensory cortical regions.